Full Press Release Details
Provides 2017 Business Outlook
KISCO, N.Y., March 06, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) ("Immudyne" or the "Company"),
a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today issued its 2017
business outlook to provide an overview of anticipated events and key milestones for the coming year, as well as a look back at
business highlights from 2016.
has experienced significant revenue growth over the past 2 years. While some of this growth came from our Beta Glucan raw material
business, most came from the launch and rapid growth of our direct-to-consumer sales operation. Immudyne's top line revenue
grew from $714,000 in 2014 to $1,250,000 in 2015 and is expected to be reported at over $5,000,000 in 2016. Management believes
2017 will be a transformative year in many ways.
accomplished the following in 2016:
goal for the remainder of 2017 is to focus on profitably scaling our Inate MD product line and to initial launch and growth of
the Shapiro MD line. Additionally, we believe there is a significant market opportunity for our Yeast Beta Glucan nutritional
supplement which we will continue to grow alongside of our core products.
Q4 2016 and Q1 2017 we began investing time and resources into an internal media buying strategy which we felt was essential to
the Company's long term success. Relying solely on third party exchanges for customer acquisition, as we did in 2016, created
artificially high customer acquisition costs and a lower quality, and a less profitable customer. We believe that our internal
media strategy will add significant value to our business, and reduce our customer acquisition costs by nearly 50% from 2016 levels,
as we enter into Q2 2017 and beyond. In addition, initial indications are that customers acquired internally are more valuable
and have greater retention than customers that are acquired through third parties. This equates to greater earnings for our shareholders
and more scalability overall for the business.
will be formally launching the Shapiro MD (www.shapiromd.com) hair loss product line in the coming weeks. This patented,
proprietary, dermatologist developed hair loss product line has huge market potential around the world. Because of the significant
investment we have made in infrastructure over the past 12 months, we have the ability to quickly scale this product line which
could have a positive near-term effect on earnings. Following the initial online launch, we are planning a national infomercial
campaign and retail placement strategy. We have already received inquiries from several national and international distributors
that wish to sell the product once it's available.
and most importantly, Immudyne's management will continue to demonstrate to shareholders that our economic interests are
identical. All key employees at Immudyne work primarily for equity, not cash compensation. The combined cash salaries of all senior
management is less than $20,000 per month. Management, affiliates, and their family members own more than 60% of Immudyne's
common stock and like you, have a large, ongoing interest in Immudyne's success.
you for being a shareholder of Immudyne. Please feel free to reach out to our Investor Relations team at investors@immudyne.com
with any additional questions you may have.
Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle
products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis
to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams
for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities.
All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the
web at www.immudyne.com.
language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made
pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press
release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may," "projects,"
"plans," "targets" and other similar language and are considered forward-looking statements. These statements
are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important
assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different
from those discussed.